The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States.
OBJECTIVE
To evaluate the cost effectiveness of voluntary prenatal and routine postnatal HIV screening in the cohort of pregnant women and newborns in the United States.


METHODS
Cost-effectiveness analysis. We developed a decision model to analyze the cost effectiveness of enhanced prenatal screening and routine newborn screening for HIV. We also analyzed the incremental cost effectiveness of routine newborn screening when improved voluntary prenatal screening is already in place.


METHODS
Analysis of the cohort of pregnant women and newborns in the United States.


METHODS
Enhanced prenatal screening, or routine newborn screening for HIV.


METHODS
Infections averted, life expectancy, costs, and incremental cost effectiveness.


RESULTS
Improved participation in voluntary prenatal HIV screening would result in an additional 1.1 million women being screened annually, would identify an additional 527 HIV-infected mothers annually, would avert 150 infections in newborns, and would cost $8,900 U.S. per life-year gained. Routine newborn HIV screening would test 3.9 million infants annually, would identify 1061 HIV-infected mothers, would avert 266 infections in newborns, and would cost $7,000 U.S. per life-year gained. If improved voluntary prenatal screening is already in place, routine newborn screening would avert an additional 135 infections in newborns, at an incremental cost of $10, 600 U.S. per life-year gained. The screening programs are likely to be cost effective over a wide range of assumptions regarding key factors in the analysis.


CONCLUSIONS
Improved voluntary prenatal HIV screening of women and routine screening of newborns are cost effective. Routine newborn screening becomes less attractive as the rate of voluntary prenatal screening increases. Improved participation in voluntary prenatal screening has the added benefit that mothers maintain their right to determine whether they are tested for HIV.
Zaric
G S
GS
Ivey School of Business, University of Western Ontario, London, Ontario, Canada.
Bayoumi
A M
AM
Brandeau
M L
ML
Owens
D K
DK
D015492:AIDS Serodiagnosis / Q000191:economics / Q000706:statistics & numerical data; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D005260:Female; D015658:HIV Infections / Q000175:diagnosis* / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control; D008403:Mass Screening / Q000191:economics* / Q000706:statistics & numerical data; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis*; D011296:Prenatal Diagnosis / Q000191:economics* / Q000706:statistics & numerical data; D014481:United States